Kura Oncology (KURA) Stock Forecast & Price Target

Kura Oncology is benefiting from a credible commercial launch of KOMZIFTI, with 2Q26 revenue of $9.1MM, 115 new patient starts, and more than 250 total prescriptions, suggesting strong physician adoption and majority share in the NPM1-mutant AML segment. Its long-term value is underpinned by compelling clinical data from KOMET-007, where ziftomenib plus 7+3 produced 96% CRc in NPM1-mutant AML, 94% 12-month OS, and central MRD-negativity in 79% of responders at <0.1%, while showing a clean safety profile and no ziftomenib-related QTc events. Financially, the company ended the quarter with $519MM in cash and expects additional collaboration payments, giving it runway to fund multiple registrational studies and expand ziftomenib across frontline AML and combination settings while advancing darlifarnib and other pipeline programs.

Kura Oncology is facing a fundamentally weak risk-reward profile because its value depends on clinical assets that may fail to show sufficient efficacy or safety, with ziftomenib and tipifarnib both exposed to development setbacks. Its commercialization path is also fragile, since tipifarnib’s strategy hinges on identifying biomarkers and securing patent protection, while FDA and foreign regulatory approvals remain uncertain and could be delayed. Even if approval is achieved, competition is intense and the company may need additional equity financing to fund development, while its focus on the smaller NUP98r segment, only 5-10% of pediatric AML patients and 2-5% of adults, limits upside and raises execution risk.